The company is now a pre-revenue clinical-stage biotech focused on SP001. Key catalysts are Phase 2 initiation in IgG4-RD (Q2 2027) and any future milestone payments from GSK on tebipenem HBr. Cash runway into H2 2029 provides a long development horizon.
Drugs in focus
SPRO drug pipeline →SP001
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
- Time to market
- 5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)
- Next catalyst
- None dated
What to watchSP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.9999entry
- T+1 · 17h ago −5.35%α −3.44% · $0.9464
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics reported Q3 2026 results with no revenue and a net loss of $44.3 million ($0.76 per share), compared to $5.4 million revenue and a $7.4 million loss in Q3 2025. The wider loss reflects a $35 million upfront payment to Innovent for in-licensing SP001, a Phase 2-ready anti-CD40L antibody for IgG4-related disease. Cash of $107.9 million funds operations into H2 2029, and the company has shifted focus from tebipenem HBr (now partnered with GSK) to immune-mediated diseases.
Key Financial Metrics
Key Facts
- No revenue in Q3 2026 vs $5.4M in Q3 2025
- Net loss of $44.3M ($0.76/share) vs $7.4M ($0.13/share) in Q3 2025
- R&D expenses $38.2M, including $35M upfront to Innovent for SP001 license
- Cash and equivalents $107.9M as of Sep 30, 2026, sufficient into H2 2029
- SP001 (anti-CD40L antibody) in-licensed from Innovent; Phase 2 in IgG4-RD planned for Q2 2027
- $105M non-recourse royalty financing closed in July 2026 with HCRx, secured against GSK's Utebzi payments
- Company has pivoted from anti-infectives (tebipenem HBr) to immune-mediated diseases
Financial Impact
Net loss widened by $36.9M YoY to $44.3M, driven by $35M upfront licensing fee; no revenue vs $5.4M prior year
Risk Factors
- No revenue and widening losses; SP001 is still in early clinical development with no approved products
- Dependence on successful Phase 2 results for SP001; IgG4-RD is a rare disease with limited precedent
- Future milestone payments from GSK on tebipenem HBr are uncertain and partially encumbered by royalty financing
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458637 |
| Document: spro-ex99_1.htm | 0001193125-26-458637 |
| Document: 0001193125-26-458637-index-headers.html | 0001193125-26-458637 |
| Document: 0001193125-26-458637-index.html | 0001193125-26-458637 |
| Document: 0001193125-26-458637.txt | 0001193125-26-458637 |
| 8-K Data (Synthetic) | 0001193125-26-458637 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers